Elicio Therapeutics Stock (NASDAQ:ELTX)


ForecastFinancialsChart

Previous Close

$4.88

52W Range

$2.96 - $11.45

50D Avg

$4.92

200D Avg

$5.97

Market Cap

$54.28M

Avg Vol (3M)

$22.81K

Beta

-

Div Yield

-

ELTX Company Profile


Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven cancers; ELI-008, a multivalent lymph node targeted AMP-peptide vaccine for mutant TP53-expressing cancers; ELI-005, a vaccine candidate for the prevention of COVID-19; ELI-011 for the treatment of hematological cancers; and ELI-012, a mKRAS TCR T cell AMP-lifier designs to use in combination with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company is headquartered in Boston, Massachusetts.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

32

IPO Date

Feb 05, 2021

Website

ELTX Performance


ELTX Financial Summary


Dec 22Dec 21Dec 20
Revenue---
Operating Income$-23.73M$-25.47M$-15.72M
Net Income$-28.21M$-26.40M$-15.71M
EBITDA$-23.28M$-25.22M$-15.53M
Basic EPS$-9.10$-8.25$-1.93
Diluted EPS$-9.10$-8.25$-1.93

Fiscal year ends in Dec 22 | Currency in USD